A double-blind, placebo-controlled trial of modafinil for cocaine dependence

Journal of Substance Abuse Treatment

Volumn 43, Issue 3, 2012, Pages 303-312

  Dackis, Charles A ^a   Kampman, Kyle M ^a   Lynch, Kevin G ^a   Plebani, Jennifer G ^a   Pettinati, Helen M ^a   Sparkman, Thorne ^a   O'Brien, Charles P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Abstinence, Addiction; Cocaine; Modafinil; Pharmacotherapy

Indexed keywords

BENZOYLECGONINE; COCAINE; MODAFINIL; PLACEBO;

ABSTINENCE; ADULT; ANXIETY; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPROVEMENT SCALE OBSERVER; CLINICAL GLOBAL IMPROVEMENT SCALE SELF; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG RETENTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEX DIFFERENCE; TREATMENT DURATION; URINALYSIS; WITHDRAWAL SYNDROME;

ADULT; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866416702     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.12.014     Document Type: Article

References (48)

1. Ahmadi J., Kampman K.M., Oslin D.M., Pettinati H.M., Dackis C., Sparkman T. Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. The American Journal on Addictions 2009, 18:81-86.
2. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., et al. Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence 2009, 104:133-139.
3. Beck A.T., Weissman A., Lester D., Trexler L. The measurement of pessimism: The hopelessness scale. Journal of Consulting and Clinical Psychology 1974, 42:861-865.
4. Bell K., Duffy P., Kalivas P.W. Context-specific enhancement of glutamate transmission by cocaine. Neuropsychopharmacology 2000, 23:335-344.
5. Dackis C.A. New treatments for cocaine abuse. Drug Discovery Today 2005, 2:79-86.
6. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
7. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., et al. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug and Alcohol Dependence 2003, 70:29-37.
8. Dackis C.A., O'Brien C.P. Cocaine dependence: A disease of the brain's reward centers. Journal of Substance Abuse Treatment 2001, 21:111-117.
9. Dackis C.A., O'Brien C.P. The neurobiology of alcoholism. Handbook of medical psychiatry 2003, 563-580. Marcel Dekker, New York. J.C. Soires, S. Gershon (Eds.).
10. Dackis C., Lynch K., Kampman K., Pettinati H., O'Brien C. Do self-reports reliably assess abstinence in cocaine dependent patients?. Neuropsychopharmacology 2005, 30:2299-2300.
11. Dackis C., O'Brien C. Glutamatergic agents for cocaine dependence. Annals of the New York Academy of Sciences 2003, 1003:328-345.
12. Deroche-Gamonet V., Darnaudery M., Bruins-Slot L., Piat F., Le Moal M., Piazza P.V. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 2002, 161:387-395.
13. Deregatis L.R., Lipman R.S. SCL-90: an outpatient psychiatric rating scale- preliminary report. Psychopharmacol Bull 1973, 9:13-28.
14. Diggle P., Heagerty P., Liang K., Zeger S. Analysis of longitudinal data 2002, Oxford University Press, Oxford. 2nd ed.
15. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I disorders-Subject edition (SCID-I/P, Version 2.0) 1996, Biometrics Research Department New York State Psychiatric Institute, New York, NY.
16. Gold L.H., Balster R.L. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996, 126:286-292.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology--Revised (DHEW Publ No ADM 76-338) 1976, 218-222. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD: U.S.
18. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and clinical Psychology 1967, 6:278-296.
19. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1969, 32:50-55.
20. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
21. Hotsenpiller G., Giorgetti M., Wolf M.E. Alterations in behaviour and glutamate transmission following presentation of stimuli previously associated with cocaine exposure. The European Journal of Neuroscience 2001, 14:1843-1855.
22. Jasinski D.R. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. Journal of Psychopharmacology 2000, 14:53-60.
23. Jasinski D.R., Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy [In Process Citation]. Clinical Neuropharmacology 2000, 23:149-156.
24. Kadden R., Carroll K., Donovan D., Cooney N., Monti P., Abrams D., et al. Cognitive-Behavioral coping skills therapy manual 1992, U.S. Government Printing Office, Washington, D.C.
25. Kalivas P.W., Duffy P. Repeated cocaine administration alters extracellular glutamate in the ventral tegmental area. Journal of Neurochemistry 1998, 70:1497-1502.
26. Kampman K.M., Alterman A.I., Volpicelli J.R., Maany I., Muller E.S., Luce D.D., et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychology of Addictive Behaviors 2001, 15:52-59.
27. Kampman K.M., Volpicelli J.R., McGinnis D.E., Alterman A.I., Weinrieb R.M., D'Angelo L., et al. Reliability and validity of the Cocaine Selective Severity Assessment. Addictive Behaviors 1998, 23:449-461.
28. Keys A.S., Mark G.P., Emre N., Meshul C.K. Reduced glutamate immunolabeling in the nucleus accumbens following extended withdrawal from self-administered cocaine. Synapse 1998, 30:393-401.
29. Malcolm R., Swayngim K., Donovan J.L., DeVane C.L., Elkashef A., Chiang N., et al. Modafinil and cocaine interactions. The American Journal of Drug and Alcohol Abuse 2006, 32:577-587.
30. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9:199-213.
31. Mignot E., Nishino S., Guilleminault C., Dement W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 17:436-437.
32. Myrick H., Malcolm R., Taylor B., LaRowe S. Modafinil: Preclinical, clinical, and post-marketing surveillance-A review of abuse liability issues. Annals of Clinical Psychiatry 2004, 16:101-109.
33. O'Brien C.P., Dackis C.A., Kampman K. Does modafinil produce euphoria?. The American Journal of Psychiatry 2006, 163:1109.
34. Patkar A.A., Thornton C.C., Berrettini W.H., Gottheil E., Weinstein S.P., Hill K.P. Predicting treatment-outcome in cocaine dependence from admission urine drug screen and peripheral serotonergic measures. Journal of Substance Abuse Treatment 2002, 23:33-40.
35. Poling J., Kosten T.R., Sofuoglu M. Treatment outcome predictors for cocaine dependence. The American Journal of Drug and Alcohol Abuse 2007, 33:191-206.
36. Preston K.L., Silverman K., Schuster C.R., Cone E.J. Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction 1997, 92:717-727.
37. Rossetti Z.L., Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. European Journal of Pharmacology 1995, 283:177-183.
38. Rush C.R., Kelly T.H., Hays L.R., Wooten A.F. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug and Alcohol Dependence 2002, 67:311-322.
39. Sheenan D.V., Lecrubier Y., Sheehan K., Janavs J., Weiller A., Schinka J., et al. The validity of the Mini International Interview (MINI) according to the SCID-P and its reliability. European Psychiatry 1997, 12:232-241.
40. Shoptaw S., Kintaudi P.C., Charuvastra C., Ling W. A screening trial of amantadine as a medication for cocaine dependence. Drug and Alcohol Dependence 2002, 66:217-224.
41. Sobell L., Sobell M. Timeline follow-back: A technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption 1992, The Humana Press, Totowa, NJ. L.A. Allen (Ed.).
42. Somoza E., Dyrenforth S., Goldsmith J., Mezinskis J., Cohen M. In search of a Universal Drug Craving Scale 1995.
43. Thomas M.J., Beurrier C., Bonci A., Malenka R.C. Long-term depression in the nucleus accumbens: A neural correlate of behavioral sensitization to cocaine. Nature Neuroscience 2001, 4:1217-1223.
44. Trujillo K.A., Akil H. Excitatory amino acids and drugs of abuse: A role for N-methyl-d-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug and Alcohol Dependence 1995, 38:139-154.
45. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA: The Journal of the American Medical Association 2009, 301:1148-1154.
46. Vosburg S.K., Hart C.L., Haney M., Rubin E., Foltin R.W. Modafinil does not serve as a reinforcer in cocaine abusers. Drug and Alcohol Dependence 2009.
47. Warot D., Corruble E., Payan C. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: A comparison with amphetamine, caffeine, and placebo. European Psychiatry 1993, 8:201-208.
48. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. The Journal of Pharmacology and Experimental Therapeutics 2009, 329:738-746.